Oral Hypoxia–Inducible Factor Prolyl Hydroxylase Inhibitor Roxadustat (FG-4592) for the Treatment of Anemia in Patients with CKD

Provenzano, Robert; Besarab, Anatole; H. Sun, Chao; A. Diamond, Susan; H. Durham, John; L. Cangiano, Jose; R. Aiello, Joseph; E. Novak, James; Lee, Tyson; Leong, Robert; K. Roberts, Brian; G. Saikali, Khalil; Hemmerich, Stefan; A. Szczech, Lynda; Peony Yu, Kin-Hung; B. Neff, Thomas

doi:10.2215/cjn.06890615

Public

Oral Hypoxia–Inducible Factor Prolyl Hydroxylase Inhibitor Roxadustat (FG-4592) for the Treatment of Anemia in Patients with CKD

Shared by NobleBlocks on Apr 19, 2016 • 12:00 AM UTC

Authors:

Robert Provenzano

Anatole Besarab

Chao H. Sun

Abstract

Background and objectives Roxadustat (FG-4592), an oral hypoxia–inducible factor prolyl hydroxylase inhibitor that stimulates erythropoiesis, regulates iron metabolism, and reduces hepcidin, was evaluated in this phase 2b study for safety, efficacy, optimal dose, and dose frequency in patients with ...

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!